Wegovy sales double to boost Novo Nordisk's fourth quarter as growth set to slow
Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the final quarter of 2024, with analysts and investors describing the results as "good enough" to ease nerves about stiff competition from rival Eli Lilly.
International Business Machines Corp. gave a stronger-than-expected revenue growth outlook for the coming years led by the ...
Estee Lauder will lay off between 5,800 and 7,000 employees after second-quarter sales plummeted 6% and operating income ...
Chipotle Mexican Grill said on Tuesday that if President Donald Trump's proposed tariffs on Mexico go into full effect, the ...
The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...
Pandora reported sales ahead of forecast thanks largely to its performance in the U.S., but economic and cost tailwinds look ...
By Juveria Tabassum and Waylon Cunningham (Reuters) -Chipotle Mexican Grill forecast tepid annual comparable sales growth on ...
Gilead Sciences, Inc.'s strong sales growth in Veklury, Livdelzi, and Trodelvy shows promise for long-term financial success.
Carlsberg A/S expects more modest operating profit growth in 2025 after losing the license to produce San Miguel beer in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback